KAZIA THERAPEUTICS LTD
KZIA · Pharmaceutical Preparations · EDGAR filings ↗
Grade
F34Going-concern micro-cap biotech near cash exhaustion with collapsing revenue and deep losses.
Strengths
- Lead asset Paxalisib has orphan/fast-track designations and an ongoing GBM AGILE Phase II/III platform trial
- R&D spend cut 58%, extending limited runway
Risks
- Only ~A$4.3M cash against A$134.8M accumulated losses; current ratio 0.35 and reliance on dilutive raises
- Net margin -493, revenue -98%, intangible impairment — distress-adjacent with no de-risking readout
Notable findings
- Restatement6 million (restated) in fiscal year 2023 to A$13 8-K ↗
- Net lossNet loss (net margin -49290.5%)
- Weak liquidityCurrent ratio 0.35 (<1)
- Revenue declineRevenue -98.2% YoY
Key metrics
Net margin
-49290.5%
Return on equity
249.4%
Return on assets
-341.6%
Revenue growth (QoQ)
-98.2%
Current ratio
0.4×
Tangible book value
-$5M
Cash & investments
$3M
Supply chain
Customers (2)
- Michael J Fox Foundation
- Vivesto AB
Suppliers (1)
- Genentech, Inc
Named in the 10-K; linked when we track them.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2025-11-07 | 2025-06-30 | 0001193125-25-272284 ↗ |
| 20-F | 2024-11-15 | 2024-06-30 | 0001193125-24-259805 ↗ |
| 20-F | 2023-10-26 | 2023-06-30 | 0001193125-23-263551 ↗ |
| 20-F | 2022-10-17 | 2022-06-30 | 0001193125-22-263335 ↗ |
| 20-F | 2021-10-07 | 2021-06-30 | 0001193125-21-293688 ↗ |
| 20-F | 2020-10-22 | 2020-06-30 | 0001193125-20-274018 ↗ |
| 20-F | 2019-10-21 | 2019-06-30 | 0001193125-19-270437 ↗ |
| 20-F | 2018-10-24 | 2018-06-30 | 0001193125-18-305893 ↗ |
| 20-F | 2017-10-25 | 2017-06-30 | 0001193125-17-318584 ↗ |
| 20-F | 2016-10-27 | 2016-06-30 | 0001193125-16-748662 ↗ |
| 20-F | 2015-10-30 | 2015-06-30 | 0001193125-15-358984 ↗ |
| 20-F | 2014-10-31 | 2014-06-30 | 0001193125-14-390367 ↗ |